Announcement on the completion of investment projects with over-raised funds and the remaining raised funds to permanently replenish working capital
Securities code: 688393 Securities abbreviation: Anbiping Announcement number: 2025-051
Guangzhou Anbiping Pharmaceutical Technology Co., Ltd.
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Important content reminder:
The name of the investment project completed this time: Pathology digitalization and intelligent application development project
The amount of the savings this time is 303,200 yuan. The next step of the use arrangement is to use the 303,200 yuan of surplus raised funds after the completion of the above-mentioned investment projects (the actual amount is based on the balance of the special account on the day when the funds are transferred out) to permanently replenish working capital and use it for the company's daily production and operations.
1. Basic situation of raised funds
Issue Name 2020 Initial Public Offering of Shares
Total funds raised were RMB 713.2704 million
Net amount of funds raised was RMB 639.9455 million
Time for receipt of raised funds: August 14, 2020
2. Completion of this fundraising project and savings of raised funds
The company's current fundraising project is the "Pathology Digital and Intelligent Application Development Project". As of the date of this announcement, the planned amount of raised funds has been basically used as required, achieving the predetermined main research and development goals. The use and savings of funds raised from the above projects are as follows:
Project name: Pathology digitalization and intelligent application development project
Closing date: October 31, 2025
Commitment to use funds raised
43 million yuan
Um
Actual use of raised funds
42.6968 million yuan
Um
The remaining amount of raised funds is RMB 303,200
Use of surplus raised funds
Flow replacement, 303,200 yuan
journey and corresponding amount
Note: The final actual transfer amount is based on the remaining amount of funds raised for the project calculated on the day the funds are transferred out.
During the implementation of the raised investment project, the company strictly abides by the relevant regulations on the use of raised funds. Based on the principles of reasonableness, economy and effectiveness, and on the premise of ensuring the smooth implementation of the project and based on the actual situation of project fund use, the company uses raised funds prudently, strengthens the control, supervision and management of expenses in each link, rationally dispatches and optimizes various resources, reasonably reduces project-related costs and expenses, and forms a savings in raised funds.
After the transfer of the remaining raised funds is completed, the company will go through the account cancellation procedures and cancel the relevant raised funds accounts. The special account supervision agreement for raised funds signed between the company, the sponsor institution and the bank where the account is opened will be terminated.
3. Applicable review procedures and sponsor’s opinions
According to the "Self-Regulatory Guidelines for Companies Listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange No. 1 - Standardized Operations", if a single or all fundraising projects are completed and the remaining raised funds (including interest income) are less than 10 million, they can be exempted from the board of directors' review procedures, and there is no need for the sponsor or independent financial adviser to issue a clear opinion. Therefore, this announcement does not require review by the board of directors, nor does the sponsor need to issue a clear opinion.
Announcement is hereby made.
Board of Directors of Guangzhou Anbiping Pharmaceutical Technology Co., Ltd.
November 18, 2025